Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil
ConclusionsICT-PCE may be a tolerable and potential option for unresectable LA-HNSCC patients ineligible for TPF.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Erbitux | Head and Neck Cancer | HNSCC | Neurology | Oral Cancer | Skin Cancer | Squamous Cell Carcinoma | Taxotere | Toxicology